If you have been reading about phase 2 trial and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-01-15. Numbers and descriptions here follow the published literature rather than marketing material.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Sharypova said she went to take a shower, during which Zverev continued berating her from outside the bathroom door. "When I got out of the shower, I was starting to take a towel and he came and said, 'Pack your stuff right now and leave,'" Sharypova recalled. "I'm just like, 'OK, can you wait a few minutes please? I'm naked here.'" From there, Sharypova said, Zverev attacked her more violently than he ever had before. She said that he grabbed her by the throat and pushed her up against the hard tile wall of the bathroom. "He started to punch me, and this time I understand that I can't be dough for punching," she said. Rothenberg reports that "Sharypova has repeatedly said that she is not interested in pursuing criminal or civil action against Zverev." She told Rothenberg she wanted to be open and honest to help other women who tend to stay silent in such situations due to fear of not being believed. Zverev secured an injunction from a Berlin court against Slate later in August 2021, barring it from publishing the assault allegations without stronger evidence. In response, Slate stated that it stands by the reporting in the article and has not removed the article from its website. They protested that the injunction was obtained without the organization having an opportunity to present evidence, and they appealed the decision. Commentator Mary Carillo stepped down from her presenting role at the 2021 Laver Cup in response to the ATP's handling of the allegations.
Peasants fled once again to the lands of the Cossacks, in particular the Yaik Host, whose people were committed to the old Cossack traditions. The changing government also burdened the Cossacks, extending its reach to reform Cossack traditions. Among ordinary Cossacks, hatred of the elite and central government rose. In 1772, a six–month open rebellion ensued between the Yaik Cossacks and the central government.
=== Histidine === Histidine complexes comprise an important subset of transition metal amino acid complexes. In common with other 4/5-substituted imidazoles, histidine can coordinate to metals via either of two nonequivalent tautomers. The free amino acid can coordinate through the imidazole and either or both of the carboxylate and amine. The imidazole side chain of histidine residues in proteins are common binding sites for metal ions. Unlike the free amino acid, the histidine residue (i.e., as a component of a peptide or protein), coordinates solely via the imidazole substituent. Examples include myoglobin (Fe), carbonic anhydrase (Zn), azurin (Cu), and alpha-ketoglutarate-dependent hydroxylases (Fe). Polyhistidine-tag ("his tag") is an amino acid motif in proteins consisting of several histidine (His) residues that is attached to proteins to facilitate purification. The concept relies on the affinity of the imidazole side chain for metal cations.
== Mechanism of action == Strychnine is a neurotoxin which acts as an antagonist of glycine and acetylcholine receptors. It primarily affects the motor nerve fibers in the spinal cord which control muscle contraction. An impulse is triggered at one end of a nerve cell by the binding of neurotransmitters to the receptors. In the presence of an inhibitory neurotransmitter, such as glycine, a greater quantity of excitatory neurotransmitters must bind to receptors before an action potential is generated. Glycine acts primarily as an agonist of the glycine receptor, which is a ligand-gated chloride channel in neurons located in the spinal cord and in the brain. This chloride channel allows the negatively charged chloride ions into the neuron, causing a hyperpolarization which pushes the membrane potential further from threshold. Strychnine is an antagonist of glycine; it binds noncovalently to the same receptor, preventing the inhibitory effects of glycine on the postsynaptic neuron. Therefore, action potentials are triggered with lower levels of excitatory neurotransmitters. When the inhibitory signals are prevented, the motor neurons are more easily activated and the victim has spastic muscle contractions, resulting in death by asphyxiation. Strychnine binds the Aplysia californica acetylcholine binding protein (a homolog of nicotinic receptors) with high affinity but low specificity, and does so in multiple conformations.
Sources: en.wikipedia.org
==== Third-party channels ==== Sometimes organizations use external agencies to create a secure and anonymous reporting channel for their employees, often referred to as a whistleblowing hotline. In addition to protecting the identity of the whistleblower, these services are designed to inform the individuals at the top of the organizational pyramid of misconduct, usually via integration with specialized case management software. Implementing a third-party solution is often the easiest way for an organization to promote compliance, or to offer a whistleblowing policy where one did not previously exist. An increasing number of companies and authorities use third-party services in which the whistleblower is also anonymous to the third-party service provider, which is made possible via toll-free phone numbers and/or web or app-based solutions that apply asymmetrical encryption.
Naturally occurring nickel (28Ni) consists of five stable isotopes; 58Ni, 60Ni, 61Ni, 62Ni and 64Ni; 58Ni is the most abundant at over 68%. 26 radioisotopes have been characterized; the most stable are 59Ni with a half-life of 81,000 years, 63Ni with a half-life of 101 years, and 56Ni at 6.075 days. All the other radioactive isotopes have half-lives of less than 60 hours and most of these have half-lives of less than 30 seconds. This element also has 11 known meta states.
Because prokaryotic mRNA does not need to be processed or transported, translation by the ribosome can begin immediately after the end of transcription. Therefore, it can be said that prokaryotic translation is coupled to transcription and occurs co-transcriptionally. In eukaryotic cells the process of translation starts with the information stored in the nucleotide sequence of DNA. This is first transformed into mRNA, then transfer RNA (tRNA) specifies which three-nucleotide codon from the genetic code corresponds to which amino acid. Eukaryotic mRNA that has been processed and transported to the cytoplasm (i.e., mature mRNA) can then be translated by ribosomes. Translation may occur at ribosomes free in the cytoplasm, or targeted to the endoplasmic reticulum by the signal recognition particle. Therefore, unlike in prokaryotes, eukaryotic translation is not directly coupled to transcription. In some contexts, protein abundance can increase even when mRNA abundance decreases, because translation efficiency and protein turnover are regulated independently of transcript levels; this has been reported for mRNA and protein levels of EEF1A1 in breast cancer.
=== Developmental stage === Adolescence is the period of greatest risk both for first use of an addictive drug and for the transition to disordered use. The prefrontal cortex, which supports planning, inhibitory control and the weighing of long-term consequences, develops more slowly than the brain's reward circuitry and is not fully mature until the mid-twenties. During this window sensitivity to reward is high while cognitive control is still developing, which contributes to greater risk-taking, including experimentation with drugs. Drug exposure in early adolescence can in turn disturb cortical development and delay prefrontal maturation, and prefrontal dysfunction in adolescents is itself associated with a higher risk of substance use disorder.
This essay discusses the fairy-story as a literary form. It was initially written as the 1939 Andrew Lang Lecture at the University of St Andrews, Scotland. Tolkien focuses on Andrew Lang's work as a folklorist and collector of fairy tales. He disagreed with Lang's broad inclusion, in his Fairy Book collections, of traveller's tales, beast fables, and other types of stories. Tolkien held a narrower perspective, viewing fairy stories as those that took place in Faerie, an enchanted realm, with or without fairies as characters. He viewed them as the natural development of the interaction of human imagination and human language.
Sources: en.wikipedia.org
February 6: Law modifying the rules for legal separation. July 15: Law on free medical assistance for people without means: women giving birth are considered equivalent to sick persons. August 19: A law concerning fire safety measures in certain regions of France holds the husband civilly liable for offenses and violations committed by his wife. July 20, 1895: Law on savings banks. December 7, 1897: Law granting women the right to be witnesses in civil status acts and in official documents in general. 1898
=== 1. Gingiva === The gingiva is the visible soft-tissue component of the periodontium and forms a biological seal around the cervical region of the teeth, protecting the underlying periodontal structures from mechanical trauma and microbial invasion.
=== Deep brain stimulation === One treatment methodology that is very promising for the treatment of camptocormia is deep brain stimulation. Previously, deep brain stimulation and bilateral stimulation of the subthalamic nucleus and/or globus pallidus internus have been used to treat patients with Parkinson's disease. Studies have shown that similar treatments could be used on patients with severe camptocormia. By using the Burke-Fahn-Marsden Dystonia Rating Scale before and after treatment, it was found that patients experienced significant functional improvement in the ability to walk.
Sulfur dioxide is sometimes used as a preservative for dried apricots, dried figs, and other dried fruits, owing to its antimicrobial properties and ability to prevent oxidation, and is called E220 when used in this way in Europe. As a preservative, it maintains the colorful appearance of the fruit and prevents rotting. Historically, molasses was "sulfured" as a preservative and also to lighten its color. Treatment of dried fruit was usually done outdoors, by igniting sublimed sulfur and burning in an enclosed space with the fruits. Fruits may be sulfured by dipping them into sodium bisulfite, sodium sulfite or sodium metabisulfite.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.